0000000000225039

AUTHOR

M. Oed

showing 3 related works from this author

Phylogenetic relationship of the green alga Nanochlorum eukaryotum deduced from its chloroplast rRNA sequences.

1995

The marine green coccoidal alga Nanochlorum eukaryotum (N.e.) is of small size with an average diameter of 1.5 microns. It is characterized by primitive-appearing biochemical and morphological properties, which are considerably different from those of other green algae. Thus, it has been proposed that N.e. may be an early developed algal form. To prove this hypothesis, DNA of N.e. was isolated by a phenol extraction procedure, and the chloroplast DNA separated by preparative CsCl density-gradient centrifugation. The kinetic complexity of the nuclear and of the chloroplast DNA was evaluated by reassociation kinetics to 3 x 10(7) bp and 9 x 10(4) bp, respectively. Several chloroplast genes, i…

ChloroplastsRNA Transfer AlaChlorellaBiologyGenes PlantDNA Ribosomal5S ribosomal RNASpecies Specificity23S ribosomal RNAChlorophytaRNA Ribosomal 16SSequence Homology Nucleic AcidBotanyGeneticsInternal transcribed spacerCloning MolecularRNA Transfer IleMolecular BiologyEcology Evolution Behavior and SystematicsPhylogenyPhylogenetic treeRibosomal RNA16S ribosomal RNAChloroplastRNA Ribosomal 23SBiochemistryChloroplast DNANucleic Acid ConformationSequence AlignmentJournal of molecular evolution
researchProduct

Identification and characterization of DNA sequences with ars-activity from the small eukaryote Nanochlorum eucaryotum

1988

biologyClinical BiochemistryGeneral Materials ScienceIdentification (biology)EukaryoteGeneral MedicineComputational biologyNanochlorum eucaryotumbiology.organism_classificationDNA sequencingAnalytical ChemistryCharacterization (materials science)Fresenius' Zeitschrift für analytische Chemie
researchProduct

PO-324 Detection of high-risk prostate cancer biomarkers by RNA sequencing and qPCR method

2018

Introduction New prognostic biomarkers for prostate cancer have the potential to overcome the clinical challenge of therapy decision and overtreatment. Present diagnostic and prognostic tests are still limited in specificity resulting in a large number of false positives and unnecessary biopsies. Furthermore, they do not enable a proper stratification between men with a high risk for an aggressive disease course requiring comprehensive therapy scheme after surgery and men with a low risk of disease recurrence cured after prostatectomy or eligible for active surveillance. In particular, patients with Gleason score 6 and 7 tumours (low and mid stage) are difficult to stratify for the appropri…

OncologyCancer ResearchCandidate genemedicine.medical_specialtyTumour heterogeneitybusiness.industryProstatectomymedicine.medical_treatmentCancerDiseasemedicine.diseaseFusion geneProstate cancerOncologyInternal medicinemedicineStage (cooking)businessESMO Open
researchProduct